| 000 | 01761 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250516173330.0 | ||
| 264 | 0 | _c20141021 | |
| 008 | 201410s 0 0 eng d | ||
| 022 | _a1365-2710 | ||
| 024 | 7 |
_a10.1111/jcpt.12097 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHinai, Y | |
| 245 | 0 | 0 |
_aAbsence of effect of SLC22A2 genotype on cisplatin-induced nephrotoxicity in oesophageal cancer patients receiving cisplatin and 5-fluorouracil: report of results discordant with those of earlier studies. _h[electronic resource] |
| 260 |
_bJournal of clinical pharmacy and therapeutics _cDec 2013 |
||
| 300 |
_a498-503 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 | _aAnalysis of Variance |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadverse effects |
| 650 | 0 | 4 | _aBlood Cell Count |
| 650 | 0 | 4 | _aChemoradiotherapy |
| 650 | 0 | 4 |
_aCisplatin _xadverse effects |
| 650 | 0 | 4 |
_aDNA _xgenetics |
| 650 | 0 | 4 |
_aElectrolytes _xblood |
| 650 | 0 | 4 |
_aEsophageal Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFluorouracil _xtherapeutic use |
| 650 | 0 | 4 | _aGenotype |
| 650 | 0 | 4 | _aGlomerular Filtration Rate |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aKidney Diseases _xchemically induced |
| 650 | 0 | 4 | _aKidney Function Tests |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aOrganic Cation Transport Proteins _xgenetics |
| 650 | 0 | 4 | _aOrganic Cation Transporter 2 |
| 650 | 0 | 4 | _aRegression Analysis |
| 700 | 1 | _aMotoyama, S | |
| 700 | 1 | _aNiioka, T | |
| 700 | 1 | _aMiura, M | |
| 773 | 0 |
_tJournal of clinical pharmacy and therapeutics _gvol. 38 _gno. 6 _gp. 498-503 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/jcpt.12097 _zAvailable from publisher's website |
| 999 |
_c23149249 _d23149249 |
||